Drugs / HepaGam B
HepaGam B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT00722332 | Feb 2008 → Oct 2013 | hepatitis B virus infection | Cangene Corporation | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT00998426 Background | Oct 2009 → Sep 2011 | hepatitis B virus infection | Georgetown University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HepaGam B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00722332 ↗ |
| Known as | HBIG | “HepaGam B (Hepatitis B Immune Globulin (HBIG))” NCT00998426 ↗ |
| Known as | Hepatitis B Immune Globulin | “HepaGam B (Hepatitis B Immune Globulin (HBIG))” NCT00998426 ↗ |
| Modality | Protein / enzyme biologic | “Hepatitis B Immunoglobulin” NCT00722332 ↗ |